Collegium Pharmaceutical Inc., of Canton, Mass., reported that a Sept. 11 joint meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee has been scheduled to review the new drug application for lead candidate Xtampza ER (oxycodone extended-release capsules).